NCI Community Oncology Research Program (NCORP)
NCI supports community-based cancer research because the majority of cancer care is provided in the community; to access large diverse patient populations; access real world healthcare delivery settings; test feasibility of new interventions/processes; and engage community oncologists in the research process to accelerate the uptake of evidence-based practice.
The NCORP clinical trials research agenda encompasses:
- Cancer prevention to identify/evaluate interventions to reduce cancer risk and incidence;
- Cancer control to reduce incidence/co-morbidity of cancer and its treatment, and to enhance quality of life;
- Cancer screening to evaluate early diagnosis interventions and cancer recurrence; and
- National Clinical Trials Network (NCTN) treatment trials to identify secondary endpoints of health-related quality of life or patient-reported outcomes.
New areas of clinical trials research will include:
- Mechanisms of symptoms and treatment related toxicities;
- Observational and longitudinal studies to understand natural history of symptoms and toxicities;
- Post-treatment surveillance (e.g. tumor markers of recurrence, optimal screening modalities);
- Under and over-diagnosis; and
- Management of pre-cancerous lesions.
In addition, NCORP's cancer care delivery research (CCDR) agenda will include a multidisciplinary field of scientific investigation that examines how social factors, financing systems, organizational structures/processes, health technologies, and healthcare provider and individual behaviors affect cancer outcomes, access to and quality of care, cancer care costs, and health and well-being of cancer patients and survivors.
The CCDR focus encompasses individuals, families, organizations, institutions, providers, communities, populations, and their interactions. The breath and scope of data collected in the repository will be determined by the NCORP Cancer Care Delivery Research Coordinating Committee.
Cancer disparities will be an important focus of all research, addressing clinical trial and cancer care delivery research questions related to the more serious, prevalent cancers and cancer-related problems which disproportionately affect racial/ethnic minorities and other underserved populations. This includes:
- Studies to enhance racial/ethnic minority and underserved participation in clinical trials;
- Studies addressing determinants of disparities (e.g., social and health care system factors, co-morbidities, and genomics); and
- Studies that evaluate differential outcomes in minority/underserved populations.
Last updated: Monday, May 19, 2014
Back to top